SEHK:2616Biotechs
Can CStone Pharmaceuticals' (SEHK:2616) Novel Antibody Drive a New Era in Allergy Treatment Innovation?
On November 7, 2025, CStone Pharmaceuticals presented promising preclinical data on its novel bispecific antibody, CS2015, at the ACAAI Annual Scientific Meeting in Orlando, showcasing its dual targeting of OX40L and TSLP in type 2 inflammation diseases.
This marks the first time CS2015 has been presented at an international conference, highlighting potential advancements in therapies for allergies, asthma, and related conditions.
We'll now explore how the innovative attributes of CS2015...